Phase I/II trial of plinabulin in combination with nivolumab and ipilimumab in patients with recurrent small cell lung cancer (SCLC): Big ten cancer research consortium (BTCRC-LUN17-127) study.

Jyoti MalhotraAlberto ChiapporiNaomi FujiokaNasser H HannaLawrence E FeldmanMalini PatelDirk MooreChunxia ChenSalma K Jabbour

Published in: Lung cancer (Amsterdam, Netherlands) (2024)

. While the clinical responses in PD-1 resistant SCLC were limited, some patients had a long duration of response. The number of ≥grade 3 irAE with the combination were lower than expected.

Keyphrases

small cell lung cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
papillary thyroid
clinical trial
prognostic factors
big data
phase iii
squamous cell carcinoma
young adults
open label
artificial intelligence